Drug intelligence / Profile preview

HRS-4029

Development stage: Phase 2
Lead developer: Beijing Suncadia Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

HRS-4029 is a chemical drug candidate developed by Beijing Suncadia Pharmaceuticals for the treatment of nervous system and cardiovascular diseases, with its primary active indication being acute ischemic stroke. The drug is currently in Phase 1 clinical trials, where it is being evaluated for safety, tolerability, and pharmacokinetics following intravenous administration. The precise mechanism of action for HRS-4029 has not been disclosed or remains unknown as of the latest updates[1][2][3][4].

Beyond the preview

Go deeper on HRS-4029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-4029.

Explore the full profile